ArticleFrontiers in immunology2025
Development of a machine learning model to predict overall survival for large hepatocellular carcinoma at BCLC stage A or B after curative hepatectomy.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From black-box prediction to transparent insight: the status quo and paradigm shift of explainable artificial intelligence in hepatocellular carcinoma research.Journal of the Egyptian National Cancer Institute · 2026Review
- The translational paradox of AI in hepatocellular carcinoma: from algorithmic over-engineering to real-world clinical utility.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Patients with large hepatocellular carcinoma (LHCC) have a poor prognosis even after curative hepatectomy. This study aimed to develop and validate an interpretable machine learning (ML) model to predict their overall survival (OS). Methods: This study included 2,565 patients with hepatocellular carcinoma (HCC) who underwent curative hepatectomy between January 2014 and December 2021. The LHCC patients were randomly assigned (7:3 ratio) to a training (n=1069) or validation (n=457) group. Independent risk factors for OS were identified using multivariable Cox regression. Eight ML models were developed and compared. The optimal model's interpretability was assessed using Shapley Additive Explanations (SHAP). Results: LHCC patients experienced a considerable reduction in OS (Hazard Ratio, HR: 1.810, 95% Confidence Interval, CI: 1.585-2.068) compared to SHCC patients. Among eight ML models, the gradient boosting machine (GBM) model demonstrated superior performance. In the validation group, the GBM model achieved area under the receiver operating characteristic curve (AUC) values of 0.742, 0.744, and 0.750 for 1-, 3-, and 5-year OS, respectively. These results were comparable with or superior to established postoperative predictive models. The GBM model showed the ability to stratify patients with LHCC into distinct prognostic groups. A web-based calculator was developed for risk score generation. Notably, the GBM model showed enhanced predictive accuracy in patients with a high neutrophil-lymphocyte ratio (C-index: 0.819). Conclusions: The GBM-based model demonstrated the potential to predict prognosis for patients with LHCC after curative hepatectomy. This interpretable model may assist in personalized risk assessment and tailoring postoperative management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.